Prophylactic therapy using epigenetic agents for RUNX1::RUNXT1-positive high-risk AML after Allo-HSCT.
Guo W, Zhang H, Zheng Y, Gao H, Zhai W, Zhang R, Ma Q, Yang D, He Y, Xia Y, Pang A, Feng S, Han M, Cao Y, Jiang E.
Guo W, et al. Among authors: han m.
Ann Hematol. 2024 Jun 22. doi: 10.1007/s00277-024-05853-2. Online ahead of print.
Ann Hematol. 2024.
PMID: 38907755